Xiuzhen Tong
Overview
Explore the profile of Xiuzhen Tong including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
13
Citations
102
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Li X, Tong X
Clin Interv Aging
. 2023 Jun;
18:921-931.
PMID: 37313310
There is overwhelming evidence indicating that the use of measurable residual disease (MRD) as a biomarker provides critical prognostic information and that MRD may have a role in directing postremission...
2.
Rong D, Chen X, Xiao J, Liu D, Ni X, Tong X, et al.
Heliyon
. 2022 Sep;
8(9):e10610.
PMID: 36164519
Objective: We tried to identify novel molecular subtypes of acute myeloid leukemia (AML) associated with histone methylation and established a relevant scoring system to predict treatment response and prognosis of...
3.
Chen X, Liu F, Rong D, Xu L, Tong X, Wang H
Anticancer Agents Med Chem
. 2021 Dec;
22(12):2274-2281.
PMID: 34963436
Background: SH3-domain-binding glutamic acid-rich protein-like protein (SH3BGRL) is downregulated in acute myeloid leukemia (AML). Clinically, DNA demethylating drug decitabine (DAC) combined with traditional chemotherapies reveals better efficacy on AML patients...
4.
Chen X, Rong D, Cai W, Tong X, Wang H
Neoplasma
. 2021 Aug;
68(4):832-841.
PMID: 34348467
Phosphatase of regenerating liver-3 (PRL-3) is recognized as a novel independent crucial driver for AML progression. Thus, the specific inhibitor of PRL-3 would be a potential therapeutic agent to AML...
5.
Liu F, Wang H, Liu J, Zhou Z, Zheng D, Huang B, et al.
Cancer Med
. 2019 Jul;
8(11):5108-5115.
PMID: 31322840
In acute myeloid leukemia (AML), myelodysplasia-related changes contribute to a poor prognosis. This retrospective, propensity score-matched study analyzed 108 newly diagnosed AML patients with features of myelodysplasia syndrome (MDS) (aged...
6.
Zhou M, Tong X
Diagn Pathol
. 2018 Sep;
13(1):69.
PMID: 30208907
This article [1] is retracted at request of the Editor.
7.
Chen M, Lu L, Li J, Zhang B, Liu J, Gu J, et al.
Oncol Lett
. 2018 Aug;
16(3):3215-3222.
PMID: 30127917
The aim of the present study was to investigate the value of systemic [F]fluorodeoxyglucose positron emission tomography (PET)/computed tomography (CT) in the diagnosis and differential diagnosis of aplastic anemia (AA)....
8.
Li J, Li X, Tong X, Liu J, Huang B, Chen M, et al.
Support Care Cancer
. 2018 Mar;
26(9):2995-3002.
PMID: 29546527
Purpose: This randomized, open-label trial was conducted to investigate the optimal duration of bed rest after intrathecal chemotherapy to reduce the incidence of complications without increasing patients' tolerance to long-term...
9.
Zhang X, Rao H, Xu X, Li Z, Liao B, Wu H, et al.
Cancer Sci
. 2017 Nov;
109(1):199-206.
PMID: 29124835
Castleman disease (CD) is a rare lymphoproliferative disorder. To assess the clinical features, outcomes, and prognostic factors of this disease, we retrospectively analyzed 185 HIV-negative CD patients from four medical...
10.
Xu L, Zhang M, Li H, Guan W, Liu B, Liu F, et al.
Leuk Lymphoma
. 2017 Jul;
59(4):918-930.
PMID: 28679293
Phosphatase PRL-3 expression is positively associated to acute myeloid leukemia (AML) progression and drug resistance. SH3-domain-binding glutamic acid-rich protein-like protein (SH3BGRL), a downstream effector of PRL-3, plays a tumor suppressive...